Ultra-short therapy for the treatment of Helicobacter pylori. (c2001)
Background: Treatment regimens for Helicobacter pylori (H. pylori) usually combine an acid reducing agent (proton-pump inhibitor, H2-antagonist) with two or three antibiotics (macrolide, metronidazole, tetracycline, amoxicillin), with a duration varying from seven to fourteen days. Recently, studies...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| التنسيق: | masterThesis |
| منشور في: |
2001
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/460 https://doi.org/10.26756/th.2001.2 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513453867139072 |
|---|---|
| author | Chahine, Corinne |
| author_facet | Chahine, Corinne |
| author_role | author |
| dc.creator.none.fl_str_mv | Chahine, Corinne |
| dc.date.none.fl_str_mv | 2001 2001-06-08 2011-05-13T08:26:54Z 2011-05-13T08:26:54Z 2011-05-13 |
| dc.identifier.none.fl_str_mv | http://hdl.handle.net/10725/460 https://doi.org/10.26756/th.2001.2 |
| dc.language.none.fl_str_mv | en |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Helicobacter pylori Helicobacter pylori infections |
| dc.title.none.fl_str_mv | Ultra-short therapy for the treatment of Helicobacter pylori. (c2001) |
| dc.type.none.fl_str_mv | Thesis info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/masterThesis |
| description | Background: Treatment regimens for Helicobacter pylori (H. pylori) usually combine an acid reducing agent (proton-pump inhibitor, H2-antagonist) with two or three antibiotics (macrolide, metronidazole, tetracycline, amoxicillin), with a duration varying from seven to fourteen days. Recently, studies have shown acceptable eradication rates using short-term triple-therapy regimens. Azithromycin, a new generation macrolide with improved pharmacokinetic properties (long t1/2 life and large volume of distribution), has been proposed for H. pylori treatment with variable radication rates of 57% to 93%. Objectives: The purpose of this study is to establish the safety and efficacy of two short-term triple-therapy regimens (lansoprazole, azithromycin and amoxicillin) for H. pylori eradication. Methods: From April 2000 to September 2000 thirty symptomatic patients with a positive rapid urease assay for H. pylori were assigned to receive either a 3-day therapy (Group A) or a 5-day therapy (Group B). In both groups, patients received lansoprazole 30mg bid on day 1; lansoprazole 30mg bid, amoxicillin 19 bid and azithromycin on days 2 and 3. Patients in group B received lansoprazole 30mg bid and amoxicillin 19 bid for two additional days (4 and 5). In-vitro antimicrobial susceptibility of H. pylori recovered from gastric biopsies was tested using the epsilometer test (E-test). Compliance and side effects were monitored. Evaluation of H. pylori eradication was done a minimum of four weeks after end of therapy using the 14C-urea breath test. |
| eu_rights_str_mv | openAccess |
| format | masterThesis |
| id | LAURepo_2677e02cfb2baad1e58fee962d243dfe |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/460 |
| publishDate | 2001 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Ultra-short therapy for the treatment of Helicobacter pylori. (c2001)Chahine, CorinneHelicobacter pyloriHelicobacter pylori infectionsBackground: Treatment regimens for Helicobacter pylori (H. pylori) usually combine an acid reducing agent (proton-pump inhibitor, H2-antagonist) with two or three antibiotics (macrolide, metronidazole, tetracycline, amoxicillin), with a duration varying from seven to fourteen days. Recently, studies have shown acceptable eradication rates using short-term triple-therapy regimens. Azithromycin, a new generation macrolide with improved pharmacokinetic properties (long t1/2 life and large volume of distribution), has been proposed for H. pylori treatment with variable radication rates of 57% to 93%. Objectives: The purpose of this study is to establish the safety and efficacy of two short-term triple-therapy regimens (lansoprazole, azithromycin and amoxicillin) for H. pylori eradication. Methods: From April 2000 to September 2000 thirty symptomatic patients with a positive rapid urease assay for H. pylori were assigned to receive either a 3-day therapy (Group A) or a 5-day therapy (Group B). In both groups, patients received lansoprazole 30mg bid on day 1; lansoprazole 30mg bid, amoxicillin 19 bid and azithromycin on days 2 and 3. Patients in group B received lansoprazole 30mg bid and amoxicillin 19 bid for two additional days (4 and 5). In-vitro antimicrobial susceptibility of H. pylori recovered from gastric biopsies was tested using the epsilometer test (E-test). Compliance and side effects were monitored. Evaluation of H. pylori eradication was done a minimum of four weeks after end of therapy using the 14C-urea breath test.1 bound copy: xii, 83 l. available at RNL.2011-05-13T08:26:54Z2011-05-13T08:26:54Z20012011-05-132001-06-08Thesisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttp://hdl.handle.net/10725/460https://doi.org/10.26756/th.2001.2eninfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/4602017-09-25T07:06:55Z |
| spellingShingle | Ultra-short therapy for the treatment of Helicobacter pylori. (c2001) Chahine, Corinne Helicobacter pylori Helicobacter pylori infections |
| status_str | publishedVersion |
| title | Ultra-short therapy for the treatment of Helicobacter pylori. (c2001) |
| title_full | Ultra-short therapy for the treatment of Helicobacter pylori. (c2001) |
| title_fullStr | Ultra-short therapy for the treatment of Helicobacter pylori. (c2001) |
| title_full_unstemmed | Ultra-short therapy for the treatment of Helicobacter pylori. (c2001) |
| title_short | Ultra-short therapy for the treatment of Helicobacter pylori. (c2001) |
| title_sort | Ultra-short therapy for the treatment of Helicobacter pylori. (c2001) |
| topic | Helicobacter pylori Helicobacter pylori infections |
| url | http://hdl.handle.net/10725/460 https://doi.org/10.26756/th.2001.2 |